OXiGENE Announces Change to Board of Directors

OXiGENE Announces Change to Board of Directors

SOUTH SAN FRANCISCO, Calif., Mar 15, 2010 (GlobeNewswire via COMTEX News Network) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that Arthur B. Laffer, Ph.D , has resigned from the Company's Board of Directors to pursue other longstanding interests, effective immediately. Dr. Laffer has served on the OXiGENE Board of Directors since 1998 and had served as Chair of the Audit Committee, the Chair of the Compensation Committee and a member of the Nominating and Governance Committee.

William N. Shiebler, Chairman of OXiGENE Board of Directors, stated, "Over the past 12 years Art Laffer has made many significant contributions to OXiGENE and provided excellent counsel and support. The entire board and I thank him for his exceptional service and wish him all the best in his future endeavors."

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: OXiGENE, Inc.

CONTACT:  OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
[email protected]

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.